BILL ANALYSIS
S3607
BULLISHAccess to Genetic Counselor Services Act of 2026
S3607 (Access to Genetic Counselor Services Act of 2026) carries an AI-assessed market impact score of 4/10 with a bullish outlook for investors. This legislation directly affects $LH, $DGX and $AMN. The primary sectors impacted are Healthcare. View the full bill text on Congress.gov.
4/10
Impact Score
bullish
Market Sentiment
3
Affected Stocks
1
Sectors Impacted
Key Takeaways for Investors
Medicare Part B will cover genetic counseling services starting January 1, 2027.
This creates a new, significant revenue stream for genetic counselors and related diagnostic testing companies.
Bipartisan sponsorship increases the bill's likelihood of passage.
How S3607 Affects the Market
The expansion of Medicare coverage for genetic counseling services will drive increased demand for genetic testing, directly benefiting diagnostic companies like LabCorp ($LH) and Quest Diagnostics ($DGX). Healthcare staffing firms, such as AMN Healthcare Services ($AMN), will experience higher demand for genetic counselors. This represents a bullish catalyst for the healthcare sector, specifically for companies involved in genetic diagnostics and counseling services.
Bill Details
| Metric | Value |
|---|---|
| Bill Number | S3607 |
| Impact Score | 4/10AI Adjustment: AI detected additional qualitative factors (+2) · Legislative Stage: Introduced |
| Market Sentiment | bullish |
| Event Date | |
| Affected Sectors | Healthcare |
| Affected Stocks | $LH, $DGX, $AMN |
| Source | View on Congress.gov → |
Summary
The Access to Genetic Counselor Services Act of 2026 expands Medicare coverage for genetic counseling services, creating a new revenue stream for genetic counselors and diagnostic testing companies. This directly increases demand for genetic testing and counseling, benefiting companies involved in these services.